A director at Viking Therapeutics Inc sold/sold after exercising options 66,756 shares at 74.690USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 55,650 shares of the Company’s common stock (RSUs) to thirteen new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awa...
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 14, 2024. Ocugen will issue a pre-market e...
HARVEY, Ill.--(BUSINESS WIRE)-- The Board of Directors of Atkore Inc. (the “Company”) (NYSE: ATKR), a leading manufacturer of electrical products for commercial, industrial, data center, telecommunications, and solar applications, today declared a quarterly cash dividend of $0.32 per share of common stock payable on May 31, 2024, to stockholders of record on May 21, 2024. About Atkore Inc. Atkore is a leading manufacturer of electrical products for commercial, industrial, data center, telecommunications, and solar applications. With 5,600 employees and $3.5B in sales in fiscal year 2023, w...
SAN JOSE, Calif.--(BUSINESS WIRE)-- BILL (NYSE: BILL), a leading financial operations platform for small and midsize businesses (SMBs), today announced financial results for the third fiscal quarter ended March 31, 2024. “We delivered strong profitable growth for the quarter, continued our rapid pace of innovation, and executed with persistent rigor and effectiveness,” said René Lacerte, BILL CEO and Founder. “During the quarter, more than 450,000 small businesses used our solutions to automate their financial operations, empowering them with more time to focus on their mission and thrive. W...
iCAD to Report First Quarter 2024 Financial Results on May 15, 2024 NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 10:00 AM Eastern Time on Wednesday, May 15, 2024. Earnings call details are as follows: Domestic: 877-545-0523International: 973-528-0016Participant Access Code: 730845Webcast: About iCAD, Inc.iCAD, Inc. (NASDAQ: ICAD) is a global leader on a missi...
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the Retina World Congress (RWC) being held May 9-12, 2024 in Ft. Lauderdale, FL. “This is a terrific opportunity to share the most recent developments in modifier gene ...
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates – Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – – Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at the 2024 ASCO Annual Meeting – STAMFORD, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- SpringWork...
eXp World Holdings Reports Q1 2024 Results BELLINGHAM, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), or the “Company”, the holding company for eXp Realty®, FrameVR.io and SUCCESS® Enterprises, today announced financial results for the first quarter ended March 31, 2024. “During the first quarter, our agents closed over $37 billion of transactions, a 12% year-over-year increase, underscoring eXp’s unparalleled scale in the cloud brokerage market we pioneered,” said Glenn Sanford, eXp World Holdings Founder, Chairman and CEO. “We continue to provid...
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024 REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results ...
Klarna and PubMatic Partner to Boost Advertiser Access to High-Intent Shopper Community New partnership will allow PubMatic’s advertisers to drive high ROI campaigns by reaching Klarna’s audiences at the point of purchase NO-HEADQUARTERS/REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced a partnership with, the AI-powered global payments network and shopping assistant, to scale programmatic access to Klarna’s native advertising inventory via PubMatic’s . Th...
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance MALVERN, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is committed to supporting adolescents facing major depressive disorder (MDD). NeuroStar TMS (transcranial magnetic stimulat...
Exagen to Announce First Quarter 2024 Results on May 13, 2024 CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT). Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 ...
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today issued the following update to shareholders from Chief Executive Officer, Oren Hershkovitz. Dear fellow shareholders, I have been serving as the Chief Executive Officer of Enlivex for the last four and a half years. During that period, we have been working diligently to develop our drug product candida...
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medicine—Phoenix will present data from the OCU400 Phas...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.